MGRX
Mangoceuticals, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$0.41
+5.30%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 315.2K | 456.0K | 615.9K | 731.5K | 8.9K |
| Cost of Revenue | 143.6K | 205.6K | 235.9K | 300.0K | 4.1K |
| Gross Profit | 171.6K | 250.4K | 380.0K | 431.5K | 4.8K |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | (2.5M) | 16.7M | 7.9M | 5.4M | 2.0M |
| General & Admin Expense | (3.1M) | 15.9M | 6.4M | 3.3M | 1.6M |
| Selling & Marketing Expense | 678.4K | 822.9K | 1.5M | 2.1M | 352.9K |
| Other Expenses | 15.8M | 2.7M | 453.8K | 4.2M | — |
| Total Operating Expenses | 13.4M | 19.4M | 8.4M | 9.7M | 2.0M |
| Cost and Expenses | 13.5M | 19.6M | 8.6M | 10.0M | 2.0M |
| Operating Income (EBIT) | (13.2M) | (19.2M) | (8.0M) | (9.2M) | (2.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 6.5K | — |
| Interest Expense | 652.2K | 103.5K | 13.7K | — | 6.5K |
| Net Interest Income | (652.2K) | (103.5K) | (13.7K) | 6.5K | (6.5K) |
| Other Non-Op Income/Expense | (1.9M) | (1.5M) | (735.0K) | 6.5K | (6.5K) |
| Non-Operating Income (excl Interest) | 1.5M | 1.4M | 721.5K | (1.1M) | — |
| EBT (Pre-Tax Income) | (15.1M) | (20.6M) | (8.7M) | (9.2M) | (2.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (15.1M) | (20.6M) | (8.7M) | (9.2M) | (2.0M) |
| Earnings from Cont. Ops | (15.1M) | (20.6M) | (8.7M) | (9.2M) | (2.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (15.4M) | (20.6M) | (8.7M) | (9.2M) | (2.0M) |
| Per Share | |||||
| Basic EPS | ($1.16) | ($2.17) | ($4.40) | ($6.45) | ($1.73) |
| Diluted EPS | ($1.16) | ($2.17) | ($4.40) | ($6.45) | ($1.73) |
| Revenue Per Share | $0.02 | $0.05 | $0.31 | $0.51 | $0.01 |
| Shares | |||||
| Basic Shares Outstanding | 17.1M | 10.1M | 2.0M | 1.4M | 1.2M |
| Diluted Shares Outstanding | 17.1M | 10.1M | 2.0M | 1.4M | 1.2M |
| Profitability Metrics | |||||
| EBITDA | (13.7M) | (18.8M) | (8.0M) | (8.1M) | (2.0M) |
| D&A | 1.0M | 1.7M | 721.5K | 24.9K | 3.9K |
| EBIT | (14.7M) | (20.5M) | (8.7M) | (8.1M) | (2.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026